Trial · NCT02096354
Adverse events172
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 172
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain | Gastrointestinal disorders | RRx-001 Followed by Irinotecan | 9 | 38 | 10 |
| other | Abdominal pain | Gastrointestinal disorders | Regorafenib Followed by Irinotecan | 6 | 13 | 7 |
| other | Enterovesical fistula | Gastrointestinal disorders | RRx-001 Followed by Irinotecan | 2 | 38 | 8 |
| other | Enterovesical fistula | Gastrointestinal disorders | Regorafenib Followed by Irinotecan | 0 | 13 | 0 |
| other | Intestinal obstruction | Gastrointestinal disorders | RRx-001 Followed by Irinotecan | 0 | 38 | 0 |
| other | Intestinal obstruction | Gastrointestinal disorders | Regorafenib Followed by Irinotecan | 1 | 13 | 1 |
| other | Small intestinal obstruction | Gastrointestinal disorders | RRx-001 Followed by Irinotecan | 4 | 38 | 17 |
| other | Small intestinal obstruction | Gastrointestinal disorders | Regorafenib Followed by Irinotecan | 0 | 13 | 0 |
| other | Stomatitis | Gastrointestinal disorders | RRx-001 Followed by Irinotecan | 0 | 38 | 0 |
| other | Stomatitis | Gastrointestinal disorders | Regorafenib Followed by Irinotecan | 1 | 13 | 1 |
| other | Disease progression | General disorders | RRx-001 Followed by Irinotecan | 7 | 38 | 47 |
| other | Disease progression | General disorders | Regorafenib Followed by Irinotecan | 2 | 13 | 2 |
| other | Fatigue | General disorders | RRx-001 Followed by Irinotecan | 16 | 38 | 22 |
| other | Fatigue | General disorders | Regorafenib Followed by Irinotecan | 7 | 13 | 8 |
| other | Hyperbilirubinaemia | Hepatobiliary disorders | RRx-001 Followed by Irinotecan | 0 | 38 | 0 |
| other | Hyperbilirubinaemia | Hepatobiliary disorders | Regorafenib Followed by Irinotecan | 4 | 13 | 4 |
| other | Urinary tract infection | Infections and infestations | RRx-001 Followed by Irinotecan | 6 | 38 | 11 |
| other | Urinary tract infection | Infections and infestations | Regorafenib Followed by Irinotecan | 2 | 13 | 6 |
| other | Infusion related reaction | Injury, poisoning and procedural complications | RRx-001 Followed by Irinotecan | 13 | 38 | 182 |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Regorafenib Followed by Irinotecan | 0 | 13 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02096354/events